Salvia miltiorrhiza Burge (Danshen) is an eminent medicinal herb that possesses broad cardiovascular and cerebrovascular protective actions and has been used in Asian countries for many centuries. Accumulating evidence suggests that Danshen and its components prevent vascular diseases, in particular, atherosclerosis and cardiac diseases, including myocardial infarction, myocardial ischemia/reperfusion injury, arrhythmia, cardiac hypertrophy and cardiac fibrosis. The published literature indicates that lipophilic constituents (tanshinone I, tanshinone IIa, tanshinone IIb, cryptotanshinone, dihydrotanshinone, etc) as well as hydrophilic constituents (danshensu, salvianolic acid A and B, protocatechuic aldehyde, etc) contribute to the cardiovascular protective actions of Danshen, suggesting a potential synergism among these constituents. Herein, we provide a systematic up-to-date review on the cardiovascular actions and therapeutic potential of major pharmacologically active constituents of Danshen. These bioactive compounds will serve as excellent drug candidates in small-molecule cardiovascular drug discovery. This article also provides a scientific rationale for understanding the traditional use of Danshen in cardiovascular therapeutics.

中文翻译：

---

丹参（丹参）：心血管疗法中的黄金草药。

丹参丹参（Dalhen miltiorrhiza Burge，丹参）是一种著名的草药，具有广泛的心血管和脑血管保护作用，已经在亚洲国家使用了多个世纪。越来越多的证据表明，丹参及其成分可预防血管疾病，尤其是动脉粥样硬化和心脏疾病，包括心肌梗塞，心肌缺血/再灌注损伤，心律不齐，心脏肥大和心脏纤维化。公开的文献表明，亲脂性成分（丹参酮I，丹参酮IIa，丹参酮IIb，隐丹参酮，二氢丹参酮等）以及亲水性成分（丹参素，丹酚酸A和B，原儿茶醛等）有助于丹参的心血管保护作用。 ，表明这些成分之间存在潜在的协同作用。在此处，我们对丹参的主要药理活性成分的心血管作用和治疗潜力进行了系统的最新综述。这些生物活性化合物将成为小分子心血管药物发现中的优秀候选药物。本文还为理解丹参在心血管疗法中的传统用法提供了科学依据。